2026-06-02T18:22:22Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/228052024-11-28T17:28:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16962col_20.500.12105_16967col_20.500.12105_16983col_20.500.12105_16984
Repisalud
author
Bellet, Meritxell
author
Ahmad, Faten
author
Villanueva, Rafael
author
Valdivia, Carolina
author
Palomino-Doza, Julian
author
Ruiz, Ada
author
Gonzalez, Xavier
author
Adrover, Encarna
author
Azaro, Analia
author
Valls-Margarit, Maria
author
Parra, Josep Lluis
author
Aguilar, Juan
author
Vidal, Maria
author
Martin, Anastasi
author
Gavila, Joaquin
author
Escriva-de-Romani, Santiago
author
Perello Martorell, Antonia
author
Hernando, Cristina
author
Lahuerta, Ainhara
author
Zamora, Pilar
author
Reyes, Victoria
author
Alcalde, Maria
author
Masanas, Helena
author
Celiz, Pamela
author
Ruiz, Isabel
author
Gil, Miguel
author
Segui, Miguel Angel
author
de la Pena, Lorena
2024-09-10T13:10:32Z
2024-09-10T13:10:32Z
2019-05
Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May;11:1-43.
10.1177/1758835919833867
1758-8359
1758-8340
Therapeutic Advances in Medical Oncology
http://hdl.handle.net/20.500.13003/9993
31205497
L627801054
2-s2.0-85066835008
https://hdl.handle.net/20.500.12105/22805
478583000001
Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
eng
CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
review article